ID   PTN11_HUMAN             Reviewed;         597 AA.
AC   Q06124; A8K1D9; Q96HD7;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 2.
DT   10-MAY-2017, entry version 210.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 11;
DE            EC=3.1.3.48 {ECO:0000269|PubMed:26742426, ECO:0000269|PubMed:28074573};
DE   AltName: Full=Protein-tyrosine phosphatase 1D;
DE            Short=PTP-1D;
DE   AltName: Full=Protein-tyrosine phosphatase 2C;
DE            Short=PTP-2C;
DE   AltName: Full=SH-PTP2;
DE            Short=SHP-2;
DE            Short=Shp2;
DE   AltName: Full=SH-PTP3;
GN   Name=PTPN11; Synonyms=PTP2C, SHPTP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=T-cell;
RX   PubMed=1281790; DOI=10.1016/0014-5793(92)81500-L;
RA   Adachi M., Sekiya M., Miyachi T., Matsuno K., Hinoda Y., Imai K.,
RA   Yachi A.;
RT   "Molecular cloning of a novel protein-tyrosine phosphatase SH-PTP3
RT   with sequence similarity to the src-homology region 2.";
RL   FEBS Lett. 314:335-339(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=1280823; DOI=10.1073/pnas.89.23.11239;
RA   Freeman R.M. Jr., Plutzky J., Neel B.G.;
RT   "Identification of a human src homology 2-containing protein-tyrosine-
RT   phosphatase: a putative homolog of Drosophila corkscrew.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:11239-11243(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), MUTAGENESIS OF CYS-463, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=8216283; DOI=10.1006/bbrc.1993.2224;
RA   Bastien L., Ramachandran C., Liu S., Adam M.;
RT   "Cloning, expression and mutational analysis of SH-PTP2, human
RT   protein-tyrosine phosphatase.";
RL   Biochem. Biophys. Res. Commun. 196:124-133(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Umbilical cord;
RX   PubMed=7681589; DOI=10.1073/pnas.90.6.2197;
RA   Ahmad S., Banville D.L., Zhao Z., Fischer E.H., Shen S.H.;
RT   "A widely expressed human protein-tyrosine phosphatase containing src
RT   homology 2 domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2197-2201(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PHOSPHORYLATION.
RX   PubMed=7681217; DOI=10.1126/science.7681217;
RA   Vogel W., Lammers R., Huang J., Ullrich A.;
RT   "Activation of a phosphotyrosine phosphatase by tyrosine
RT   phosphorylation.";
RL   Science 259:1611-1614(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PHOSPHORYLATION, AND INTERACTION WITH PDGFRB.
RX   PubMed=7691811;
RA   Lechleider R.J., Sugimoto S., Bennett A.M., Kashishian A.S.,
RA   Cooper J.A., Shoelson S.E., Walsh C.T., Neel B.G.;
RT   "Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2
RT   by its binding site, phosphotyrosine 1009, on the human platelet-
RT   derived growth factor receptor.";
RL   J. Biol. Chem. 268:21478-21481(1993).
RN   [11]
RP   PHOSPHORYLATION BY PDGFRB.
RX   PubMed=8041791; DOI=10.1073/pnas.91.15.7335;
RA   Bennett A.M., Tang T.L., Sugimoto S., Walsh C.T., Neel B.G.;
RT   "Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth
RT   factor receptor beta to Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:7335-7339(1994).
RN   [12]
RP   INTERACTION WITH PTPNS1.
RX   PubMed=8810330; DOI=10.1074/jbc.271.41.25569;
RA   Ohnishi H., Kubota M., Ohtake A., Sato K., Sano S.;
RT   "Activation of protein-tyrosine phosphatase SH-PTP2 by a tyrosine-
RT   based activation motif of a novel brain molecule.";
RL   J. Biol. Chem. 271:25569-25574(1996).
RN   [13]
RP   INTERACTION WITH PTPNS1.
RX   PubMed=9062191; DOI=10.1038/386181a0;
RA   Kharitonenkov A., Chen Z., Sures I., Wang H., Schilling J.,
RA   Ullrich A.;
RT   "A family of proteins that inhibit signalling through tyrosine kinase
RT   receptors.";
RL   Nature 386:181-186(1997).
RN   [14]
RP   INTERACTION WITH FLT1.
RX   PubMed=9600074; DOI=10.1006/bbrc.1998.8578;
RA   Igarashi K., Isohara T., Kato T., Shigeta K., Yamano T., Uno I.;
RT   "Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.";
RL   Biochem. Biophys. Res. Commun. 246:95-99(1998).
RN   [15]
RP   INTERACTION WITH GAB2.
RX   PubMed=10068651;
RA   Nishida K., Yoshida Y., Itoh M., Fukada T., Ohtani T., Shirogane T.,
RA   Atsumi T., Takahashi-Tezuka M., Ishihara K., Hibi M., Hirano T.;
RT   "Gab-family adapter proteins act downstream of cytokine and growth
RT   factor receptors and T- and B-cell antigen receptors.";
RL   Blood 93:1809-1816(1999).
RN   [16]
RP   INTERACTION WITH SIT1.
RX   PubMed=10209036; DOI=10.1084/jem.189.8.1181;
RA   Marie-Cardine A., Kirchgessner H., Bruyns E., Shevchenko A., Mann M.,
RA   Autschbach F., Ratnofsky S., Meuer S., Schraven B.;
RT   "SHP2-interacting transmembrane adaptor protein (SIT), a novel
RT   disulfide-linked dimer regulating human T-cell activation.";
RL   J. Exp. Med. 189:1181-1194(1999).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH EPHA2.
RX   PubMed=10655584; DOI=10.1038/35000008;
RA   Miao H., Burnett E., Kinch M., Simon E., Wang B.;
RT   "Activation of EphA2 kinase suppresses integrin function and causes
RT   focal-adhesion-kinase dephosphorylation.";
RL   Nat. Cell Biol. 2:62-69(2000).
RN   [18]
RP   INTERACTION WITH MZPL1, AND DEPHOSPHORYLATION OF MZPL1.
RX   PubMed=10681522; DOI=10.1074/jbc.275.8.5453;
RA   Zhao R., Zhao Z.J.;
RT   "Dissecting the interaction of SHP-2 with PZR, an immunoglobulin
RT   family protein containing immunoreceptor tyrosine-based inhibitory
RT   motifs.";
RL   J. Biol. Chem. 275:5453-5459(2000).
RN   [19]
RP   INTERACTION WITH FCRL3.
RX   PubMed=11162587; DOI=10.1006/bbrc.2000.4213;
RA   Xu M.-J., Zhao R., Zhao Z.J.;
RT   "Molecular cloning and characterization of SPAP1, an inhibitory
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 280:768-775(2001).
RN   [20]
RP   INTERACTION WITH CD84.
RX   PubMed=11389028; DOI=10.1182/blood.V97.12.3867;
RA   Sayos J., Martin M., Chen A., Simarro M., Howie D., Morra M.,
RA   Engel P., Terhorst C.;
RT   "Cell surface receptors Ly-9 and CD84 recruit the X-linked
RT   lymphoproliferative disease gene product SAP.";
RL   Blood 97:3867-3874(2001).
RN   [21]
RP   INTERACTION WITH CD84.
RX   PubMed=11414741; DOI=10.1006/clim.2001.5035;
RA   Lewis J., Eiben L.J., Nelson D.L., Cohen J.I., Nichols K.E.,
RA   Ochs H.D., Notarangelo L.D., Duckett C.S.;
RT   "Distinct interactions of the X-linked lymphoproliferative syndrome
RT   gene product SAP with cytoplasmic domains of members of the CD2
RT   receptor family.";
RL   Clin. Immunol. 100:15-23(2001).
RN   [22]
RP   INTERACTION WITH SIT1.
RX   PubMed=11433379;
RX   DOI=10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V;
RA   Pfrepper K.-I., Marie-Cardine A., Simeoni L., Kuramitsu Y., Leo A.,
RA   Spicka J., Hilgert I., Scherer J., Schraven B.;
RT   "Structural and functional dissection of the cytoplasmic domain of the
RT   transmembrane adaptor protein SIT (SHP2-interacting transmembrane
RT   adaptor protein).";
RL   Eur. J. Immunol. 31:1825-1836(2001).
RN   [23]
RP   INTERACTION WITH FER AND PECAM1.
RX   PubMed=12972546; DOI=10.1091/mbc.E03-02-0080;
RA   Kogata N., Masuda M., Kamioka Y., Yamagishi A., Endo A., Okada M.,
RA   Mochizuki N.;
RT   "Identification of Fer tyrosine kinase localized on microtubules as a
RT   platelet endothelial cell adhesion molecule-1 phosphorylating kinase
RT   in vascular endothelial cells.";
RL   Mol. Biol. Cell 14:3553-3564(2003).
RN   [24]
RP   INTERACTION WITH FCRL4.
RX   PubMed=14597715; DOI=10.1073/pnas.1935944100;
RA   Ehrhardt G.R.A., Davis R.S., Hsu J.T., Leu C.-M., Ehrhardt A.,
RA   Cooper M.D.;
RT   "The inhibitory potential of Fc receptor homolog 4 on memory B
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:13489-13494(2003).
RN   [25]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [26]
RP   INTERACTION WITH FLT4.
RX   PubMed=15102829; DOI=10.1074/jbc.M314015200;
RA   Wang J.F., Zhang X., Groopman J.E.;
RT   "Activation of vascular endothelial growth factor receptor-3 and its
RT   downstream signaling promote cell survival under oxidative stress.";
RL   J. Biol. Chem. 279:27088-27097(2004).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [28]
RP   INTERACTION WITH ANKHD1.
RX   PubMed=16956752; DOI=10.1016/j.bbadis.2006.07.010;
RA   Traina F., Favaro P.M.B., Medina Sde S., Duarte Ada S.,
RA   Winnischofer S.M., Costa F.F., Saad S.T.O.;
RT   "ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed
RT   in acute leukemias and is associated with SHP2 in K562 cells.";
RL   Biochim. Biophys. Acta 1762:828-834(2006).
RN   [29]
RP   INTERACTION WITH ROS1.
RX   PubMed=16885344; DOI=10.1158/0008-5472.CAN-06-1193;
RA   Charest A., Wilker E.W., McLaughlin M.E., Lane K., Gowda R., Coven S.,
RA   McMahon K., Kovach S., Feng Y., Yaffe M.B., Jacks T., Housman D.;
RT   "ROS fusion tyrosine kinase activates a SH2 domain-containing
RT   phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of
RT   rapamycin signaling axis to form glioblastoma in mice.";
RL   Cancer Res. 66:7473-7481(2006).
RN   [30]
RP   INTERACTION WITH FCRL6.
RX   PubMed=17213291; DOI=10.1182/blood-2006-06-030023;
RA   Wilson T.J., Presti R.M., Tassi I., Overton E.T., Cella M.,
RA   Colonna M.;
RT   "FcRL6, a new ITIM-bearing receptor on cytolytic cells, is broadly
RT   expressed by lymphocytes following HIV-1 infection.";
RL   Blood 109:3786-3793(2007).
RN   [31]
RP   INTERACTION WITH TERT, AND FUNCTION.
RX   PubMed=18829466; DOI=10.1074/jbc.M805138200;
RA   Jakob S., Schroeder P., Lukosz M., Buchner N., Spyridopoulos I.,
RA   Altschmied J., Haendeler J.;
RT   "Nuclear protein tyrosine phosphatase Shp-2 is one important negative
RT   regulator of nuclear export of telomerase reverse transcriptase.";
RL   J. Biol. Chem. 283:33155-33161(2008).
RN   [32]
RP   FUNCTION.
RX   PubMed=18559669; DOI=10.1083/jcb.200710187;
RA   Lee H.H., Chang Z.F.;
RT   "Regulation of RhoA-dependent ROCKII activation by Shp2.";
RL   J. Cell Biol. 181:999-1012(2008).
RN   [33]
RP   INTERACTION WITH KIR2DL1.
RX   PubMed=18604210; DOI=10.1038/ni.1635;
RA   Yu M.-C., Su L.-L., Zou L., Liu Y., Wu N., Kong L., Zhuang Z.-H.,
RA   Sun L., Liu H.P., Hu J.-H., Li D., Strominger J.L., Zang J.-W.,
RA   Pei G., Ge B.-X.;
RT   "An essential function for beta-arrestin 2 in the inhibitory signaling
RT   of natural killer cells.";
RL   Nat. Immunol. 9:898-907(2008).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [35]
RP   INTERACTION WITH GAREM1.
RX   PubMed=19509291; DOI=10.1074/jbc.M109.021139;
RA   Tashiro K., Tsunematsu T., Okubo H., Ohta T., Sano E., Yamauchi E.,
RA   Taniguchi H., Konishi H.;
RT   "GAREM, a novel adaptor protein for growth factor receptor-bound
RT   protein 2, contributes to cellular transformation through the
RT   activation of extracellular signal-regulated kinase signaling.";
RL   J. Biol. Chem. 284:20206-20214(2009).
RN   [36]
RP   INTERACTION WITH PECAM1.
RX   PubMed=19342684; DOI=10.4049/jimmunol.0803192;
RA   Dasgupta B., Dufour E., Mamdouh Z., Muller W.A.;
RT   "A novel and critical role for tyrosine 663 in platelet endothelial
RT   cell adhesion molecule-1 trafficking and transendothelial migration.";
RL   J. Immunol. 182:5041-5051(2009).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-62 AND TYR-584, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   PHOSPHORYLATION, AND INTERACTION WITH PDGFRB.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [39]
RP   INVOLVEMENT IN MC.
RX   PubMed=20577567; DOI=10.1371/journal.pgen.1000991;
RA   Sobreira N.L., Cirulli E.T., Avramopoulos D., Wohler E., Oswald G.L.,
RA   Stevens E.L., Ge D., Shianna K.V., Smith J.P., Maia J.M., Gumbs C.E.,
RA   Pevsner J., Thomas G., Valle D., Hoover-Fong J.E., Goldstein D.B.;
RT   "Whole-genome sequencing of a single proband together with linkage
RT   analysis identifies a Mendelian disease gene.";
RL   PLoS Genet. 6:E1000991-E1000991(2010).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-584, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 3-530 (ISOFORM 2).
RX   PubMed=9491886; DOI=10.1016/S0092-8674(00)80938-1;
RA   Hof P., Pluskey S., Dhe-Paganon S., Eck M.J., Shoelson S.E.;
RT   "Crystal structure of the tyrosine phosphatase SHP-2.";
RL   Cell 92:441-450(1998).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 237-533.
RX   PubMed=19167335; DOI=10.1016/j.cell.2008.11.038;
RA   Barr A.J., Ugochukwu E., Lee W.H., King O.N.F., Filippakopoulos P.,
RA   Alfano I., Savitsky P., Burgess-Brown N.A., Mueller S., Knapp S.;
RT   "Large-scale structural analysis of the classical human protein
RT   tyrosine phosphatome.";
RL   Cell 136:352-363(2009).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 262-532 IN COMPLEX WITH
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=20170098; DOI=10.1021/jm901645u;
RA   Zhang X., He Y., Liu S., Yu Z., Jiang Z.X., Yang Z., Dong Y.,
RA   Nabinger S.C., Wu L., Gunawan A.M., Wang L., Chan R.J., Zhang Z.Y.;
RT   "Salicylic acid based small molecule inhibitor for the oncogenic Src
RT   homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).";
RL   J. Med. Chem. 53:2482-2493(2010).
RN   [47]
RP   VARIANTS NS1 GLY-61; CYS-63; GLY-72; SER-72; ASP-76; ARG-79; VAL-282;
RP   ASP-308 AND VAL-508.
RX   PubMed=11704759; DOI=10.1038/ng772;
RA   Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G.,
RA   Kremer H., van der Burgt I., Crosby A.H., Ion A., Jeffery S.,
RA   Kalidas K., Patton M.A., Kucherlapati R.S., Gelb B.D.;
RT   "Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2,
RT   cause Noonan syndrome.";
RL   Nat. Genet. 29:465-468(2001).
RN   [48]
RP   ERRATUM.
RA   Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G.,
RA   Kremer H., van der Burgt I., Crosby A.H., Ion A., Jeffery S.,
RA   Kalidas K., Patton M.A., Kucherlapati R.S., Gelb B.D.;
RL   Nat. Genet. 29:491-491(2001).
RN   [49]
RP   ERRATUM.
RA   Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G.,
RA   Kremer H., van der Burgt I., Crosby A.H., Ion A., Jeffery S.,
RA   Kalidas K., Patton M.A., Kucherlapati R.S., Gelb B.D.;
RL   Nat. Genet. 30:123-123(2001).
RN   [50]
RP   VARIANTS NS1 ALA-42; ALA-60; ASN-61; GLY-61; ASP-62; CYS-63; GLY-72;
RP   ILE-73; ASP-76; ARG-79; ALA-106; ASP-139; CYS-279; VAL-282; LEU-285;
RP   SER-285; ASP-308; SER-308; VAL-309; LYS-505 AND VAL-508.
RX   PubMed=11992261; DOI=10.1086/340847;
RA   Tartaglia M., Kalidas K., Shaw A., Song X., Musat D.L.,
RA   van der Burgt I., Brunner H.G., Bertola D.R., Crosby A.H., Ion A.,
RA   Kucherlapati R.S., Jeffery S., Patton M.A., Gelb B.D.;
RT   "PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-
RT   phenotype correlation, and phenotypic heterogeneity.";
RL   Am. J. Hum. Genet. 70:1555-1563(2002).
RN   [51]
RP   VARIANTS LPRD1 CYS-279 AND MET-472.
RX   PubMed=12058348; DOI=10.1086/341528;
RA   Digilio M.C., Conti E., Sarkozy A., Mingarelli R., Dottorini T.,
RA   Marino B., Pizzuti A., Dallapiccola B.;
RT   "Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the
RT   PTPN11 gene.";
RL   Am. J. Hum. Genet. 71:389-394(2002).
RN   [52]
RP   VARIANTS NS1 ASP-62; CYS-63 AND THR-506.
RX   PubMed=12325025; DOI=10.1002/humu.10129;
RA   Maheshwari M., Belmont J., Fernbach S., Ho T., Molinari L., Yakub I.,
RA   Yu F., Combes A., Towbin J.A., Craigen W.J., Gibbs R.A.;
RT   "PTPN11 mutations in Noonan syndrome type I: detection of recurrent
RT   mutations in exons 3 and 13.";
RL   Hum. Mutat. 20:298-304(2002).
RN   [53]
RP   VARIANTS NS1 GLY-61; CYS-63; SER-72; ILE-73; SER-285 AND ASP-308.
RX   PubMed=12161469; DOI=10.1210/jcem.87.8.8694;
RA   Kosaki K., Suzuki T., Muroya K., Hasegawa T., Sato S., Matsuo N.,
RA   Kosaki R., Nagai T., Hasegawa Y., Ogata T.;
RT   "PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations
RT   in seven Japanese patients with Noonan syndrome.";
RL   J. Clin. Endocrinol. Metab. 87:3529-3533(2002).
RN   [54]
RP   VARIANT NS1 ARG-79.
RX   PubMed=12529711; DOI=10.1038/sj.ejhg.5200915;
RA   Schollen E., Matthijs G., Gewillig M., Fryns J.-P., Legius E.;
RT   "PTPN11 mutation in a large family with Noonan syndrome and dizygous
RT   twinning.";
RL   Eur. J. Hum. Genet. 11:85-88(2003).
RN   [55]
RP   VARIANTS NS1 LYS-58; ASN-61; GLY-61; CYS-63; GLN-69; LEU-71; SER-72;
RP   ILE-73; ASP-76; ARG-79; ASP-139; ARG-256; VAL-282 AND ASP-308.
RX   PubMed=12634870; DOI=10.1038/sj.ejhg.5200935;
RA   Musante L., Kehl H.G., Majewski F., Meinecke P., Schweiger S.,
RA   Gillessen-Kaesbach G., Wieczorek D., Hinkel G.K., Tinschert S.,
RA   Hoeltzenbein M., Ropers H.-H., Kalscheuer V.M.;
RT   "Spectrum of mutations in PTPN11 and genotype-phenotype correlation in
RT   96 patients with Noonan syndrome and five patients with cardio-facio-
RT   cutaneous syndrome.";
RL   Eur. J. Hum. Genet. 11:201-206(2003).
RN   [56]
RP   ERRATUM.
RA   Musante L., Kehl H.G., Majewski F., Meinecke P., Schweiger S.,
RA   Gillessen-Kaesbach G., Wieczorek D., Hinkel G.K., Tinschert S.,
RA   Hoeltzenbein M., Ropers H.-H., Kalscheuer V.M.;
RL   Eur. J. Hum. Genet. 11:551-551(2003).
RN   [57]
RP   VARIANT NS1 THR-506.
RX   PubMed=12739139; DOI=10.1007/s00431-003-1227-6;
RA   Kondoh T., Ishii E., Aoki Y., Shimizu T., Zaitsu M., Matsubara Y.,
RA   Moriuchi H.;
RT   "Noonan syndrome with leukaemoid reaction and overproduction of
RT   catecholamines: a case report.";
RL   Eur. J. Pediatr. 162:548-549(2003).
RN   [58]
RP   VARIANT LPRD1 PRO-510.
RX   PubMed=14961557; DOI=10.1002/humu.9149;
RA   Conti E., Dottorini T., Sarkozy A., Tiller G.E., Esposito G.,
RA   Pizzuti A., Dallapiccola B.;
RT   "A novel PTPN11 mutation in LEOPARD syndrome.";
RL   Hum. Mutat. 21:654-654(2003).
RN   [59]
RP   VARIANTS NS1 ILE-2; ALA-42; ASP-62; CYS-63; GLY-72; PRO-79; ALA-106;
RP   CYS-279; ASP-308; SER-308; MET-472; ARG-507; VAL-508 AND PHE-564.
RX   PubMed=12960218; DOI=10.1136/jmg.40.9.704;
RA   Sarkozy A., Conti E., Seripa D., Digilio M.C., Grifone N., Tandoi C.,
RA   Fazio V.M., Di Ciommo V., Marino B., Pizzuti A., Dallapiccola B.;
RT   "Correlation between PTPN11 gene mutations and congenital heart
RT   defects in Noonan and LEOPARD syndromes.";
RL   J. Med. Genet. 40:704-708(2003).
RN   [60]
RP   VARIANTS JMML TYR-61; VAL-61; LYS-69; THR-72; VAL-72; ALA-76; GLY-76;
RP   LYS-76; VAL-76; ALA-507 AND ARG-507, VARIANTS MYELODYSPLASTIC SYNDROME
RP   VAL-60; VAL-61; LYS-69; LEU-71 AND ALA-76, VARIANTS NS1 ASP-62 AND
RP   ILE-73, AND VARIANT ACUTE MYELOID LEUKEMIA LYS-71.
RX   PubMed=12717436; DOI=10.1038/ng1156;
RA   Tartaglia M., Niemeyer C.M., Fragale A., Song X., Buechner J.,
RA   Jung A., Haehlen K., Hasle H., Licht J.D., Gelb B.D.;
RT   "Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia,
RT   myelodysplastic syndromes and acute myeloid leukemia.";
RL   Nat. Genet. 34:148-150(2003).
RN   [61]
RP   VARIANT NS1 MET-415.
RX   PubMed=15384080; DOI=10.1002/ajmg.a.30270;
RA   Bertola D.R., Pereira A.C., de Oliveira P.S.L., Kim C.A.,
RA   Krieger J.E.;
RT   "Clinical variability in a Noonan syndrome family with a new PTPN11
RT   gene mutation.";
RL   Am. J. Med. Genet. A 130:378-383(2004).
RN   [62]
RP   VARIANTS LPRD1 THR-465 AND ALA-468.
RX   PubMed=15389709; DOI=10.1002/ajmg.a.30281;
RA   Yoshida R., Nagai T., Hasegawa T., Kinoshita E., Tanaka T., Ogata T.;
RT   "Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome.";
RL   Am. J. Med. Genet. A 130:432-434(2004).
RN   [63]
RP   VARIANTS LPRD1 CYS-279; SER-279; MET-472 AND PRO-514.
RX   PubMed=15520399; DOI=10.1136/jmg.2004.021451;
RG   French collaborative Noonan study group;
RA   Keren B., Hadchouel A., Saba S., Sznajer Y., Bonneau D., Leheup B.,
RA   Boute O., Gaillard D., Lacombe D., Layet V., Marlin S., Mortier G.,
RA   Toutain A., Beylot C., Baumann C., Verloes A., Cave H.;
RT   "PTPN11 mutations in patients with LEOPARD syndrome: a French
RT   multicentric experience.";
RL   J. Med. Genet. 41:E117-E117(2004).
RN   [64]
RP   VARIANTS LPRD1 CYS-279; SER-279; ALA-468; MET-472; TRP-502; LEU-502
RP   AND PRO-510.
RX   PubMed=15121796; DOI=10.1136/jmg.2003.013466;
RA   Sarkozy A., Conti E., Digilio M.C., Marino B., Morini E., Pacileo G.,
RA   Wilson M., Calabro R., Pizzuti A., Dallapiccola B.;
RT   "Clinical and molecular analysis of 30 patients with multiple
RT   lentigines LEOPARD syndrome.";
RL   J. Med. Genet. 41:E68-E68(2004).
RN   [65]
RP   VARIANT NS1 ARG-510.
RX   PubMed=15948193; DOI=10.1002/ajmg.a.30813;
RA   Bertola D.R., Pereira A.C., Passetti F., de Oliveira P.S.L.,
RA   Messiaen L., Gelb B.D., Kim C.A., Krieger J.E.;
RT   "Neurofibromatosis-Noonan syndrome: molecular evidence of the
RT   concurrence of both disorders in a patient.";
RL   Am. J. Med. Genet. A 136:242-245(2005).
RN   [66]
RP   VARIANT NS1 GLU-514.
RX   PubMed=15889278; DOI=10.1007/s00431-005-1679-y;
RA   Takahashi K., Kogaki S., Kurotobi S., Nasuno S., Ohta M., Okabe H.,
RA   Wada K., Sakai N., Taniike M., Ozono K.;
RT   "A novel mutation in the PTPN11 gene in a patient with Noonan syndrome
RT   and rapidly progressive hypertrophic cardiomyopathy.";
RL   Eur. J. Pediatr. 164:497-500(2005).
RN   [67]
RP   VARIANT LPRD1 PRO-510.
RX   PubMed=15690106; DOI=10.1007/s10038-004-0212-x;
RA   Kalidas K., Shaw A.C., Crosby A.H., Newbury-Ecob R., Greenhalgh L.,
RA   Temple I.K., Law C., Patel A., Patton M.A., Jeffery S.;
RT   "Genetic heterogeneity in LEOPARD syndrome: two families with no
RT   mutations in PTPN11.";
RL   J. Hum. Genet. 50:21-25(2005).
RN   [68]
RP   VARIANT LPRD1 GLU-514.
RX   PubMed=16733669; DOI=10.1007/s00431-006-0163-7;
RA   Digilio M.C., Sarkozy A., Pacileo G., Limongelli G., Marino B.,
RA   Dallapiccola B.;
RT   "PTPN11 gene mutations: linking the Gln510Glu mutation to the 'LEOPARD
RT   syndrome phenotype'.";
RL   Eur. J. Pediatr. 165:803-805(2006).
RN   [69]
RP   VARIANT LPRD1 CYS-279.
RX   PubMed=16679933; DOI=10.1097/01.mph.0000199590.21797.0b;
RA   Ucar C., Calyskan U., Martini S., Heinritz W.;
RT   "Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11
RT   gene mutation positive).";
RL   J. Pediatr. Hematol. Oncol. 28:123-125(2006).
RN   [70]
RP   VARIANT NS1 ALA-59.
RX   PubMed=19020799; DOI=10.1007/s10038-008-0343-6;
RA   Ko J.M., Kim J.M., Kim G.H., Yoo H.W.;
RT   "PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype
RT   correlation in Korean patients with Noonan syndrome.";
RL   J. Hum. Genet. 53:999-1006(2008).
RN   [71]
RP   VARIANT NS1 SER-495, VARIANT LPRD1 TRP-502, CHARACTERIZATION OF
RP   VARIANTS NS1 SER-495, AND CHARACTERIZATION OF VARIANT LPRD1 TRP-502.
RX   PubMed=24891296; DOI=10.1002/ajmg.a.36620;
RA   Edwards J.J., Martinelli S., Pannone L., Lo I.F., Shi L., Edelmann L.,
RA   Tartaglia M., Luk H.M., Gelb B.D.;
RT   "A PTPN11 allele encoding a catalytically impaired SHP2 protein in a
RT   patient with a Noonan syndrome phenotype.";
RL   Am. J. Med. Genet. A 164:2351-2355(2014).
RN   [72]
RP   VARIANT JMML LYS-76, CHARACTERIZATION OF VARIANT JMML LYS-76, VARIANTS
RP   LPRD1 CYS-279; MET-472; PRO-510 AND GLU-514, CHARACTERIZATION OF
RP   VARIANTS LPRD1 CYS-279; MET-472; PRO-510 AND GLU-514, FUNCTION,
RP   CATALYTIC ACTIVITY, INTERACTION WITH CDC73, AND SUBCELLULAR LOCATION.
RX   PubMed=26742426; DOI=10.1016/j.bbrc.2015.12.117;
RA   Noda S., Takahashi A., Hayashi T., Tanuma S., Hatakeyama M.;
RT   "Determination of the catalytic activity of LEOPARD syndrome-
RT   associated SHP2 mutants toward parafibromin, a bona fide SHP2
RT   substrate involved in Wnt signaling.";
RL   Biochem. Biophys. Res. Commun. 469:1133-1139(2016).
RN   [73]
RP   VARIANTS NS1 HIS-261; PHE-261; ARG-262; PHE-262 AND GLN-265,
RP   CHARACTERIZATION VARIANTS NS1 HIS-261; PHE-261; ARG-262; PHE-262 AND
RP   GLN-265, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=28074573; DOI=10.1002/humu.23175;
RA   Pannone L., Bocchinfuso G., Flex E., Rossi C., Baldassarre G.,
RA   Lissewski C., Pantaleoni F., Consoli F., Lepri F., Magliozzi M.,
RA   Anselmi M., Delle Vigne S., Sorge G., Karaer K., Cuturilo G.,
RA   Sartorio A., Tinschert S., Accadia M., Digilio M.C., Zampino G.,
RA   De Luca A., Cav e H., Zenker M., Gelb B.D., Dallapiccola B.,
RA   Stella L., Ferrero G.B., Martinelli S., Tartaglia M.;
RT   "Structural, Functional, and Clinical Characterization of a Novel
RT   PTPN11 Mutation Cluster Underlying Noonan Syndrome.";
RL   Hum. Mutat. 0:0-0(2017).
CC   -!- FUNCTION: Acts downstream of various receptor and cytoplasmic
CC       protein tyrosine kinases to participate in the signal transduction
CC       from the cell surface to the nucleus. Positively regulates MAPK
CC       signal transduction pathway (PubMed:28074573). Dephosphorylates
CC       GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2
CC       at 'Tyr-722' resulting in stimulatation of its RhoA binding
CC       activity. Dephosphorylates CDC73 (PubMed:26742426).
CC       {ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:18559669,
CC       ECO:0000269|PubMed:18829466, ECO:0000269|PubMed:26742426,
CC       ECO:0000269|PubMed:28074573}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044,
CC       ECO:0000269|PubMed:20170098, ECO:0000269|PubMed:26742426,
CC       ECO:0000269|PubMed:28074573}.
CC   -!- SUBUNIT: Interacts with phosphorylated LIME1 and BCAR3. Interacts
CC       with SHB and INPP5D/SHIP1 (By similarity). Interacts with MILR1
CC       (tyrosine-phosphorylated). Interacts with FLT1 (tyrosine-
CC       phosphorylated), FLT3 (tyrosine-phosphorylated), FLT4 (tyrosine-
CC       phosphorylated), KIT and GRB2. Interacts with PDGFRA (tyrosine
CC       phosphorylated). Interacts (via SH2 domain) with TEK/TIE2
CC       (tyrosine phosphorylated) (By similarity). Interacts with PTPNS1
CC       and CD84. Interacts with phosphorylated SIT1 and MPZL1. Interacts
CC       with FCRL3, FCRL4, FCRL6 and ANKHD1. Interacts with KIR2DL1; the
CC       interaction is enhanced by ARRB2. Interacts with GAB2. Interacts
CC       with TERT; the interaction retains TERT in the nucleus. Interacts
CC       with PECAM1 and FER. Interacts with EPHA2 (activated);
CC       participates in PTK2/FAK1 dephosphorylation in EPHA2 downstream
CC       signaling. Interacts with ROS1; mediates PTPN11 phosphorylation.
CC       Interacts with PDGFRB (tyrosine phosphorylated); this interaction
CC       increases the PTPN11 phosphatase activity. Interacts with GAREM1
CC       isoform 1 (tyrosine phosphorylated); the interaction increases
CC       MAPK/ERK activity and does not affect the GRB2/SOS complex
CC       formation. Interacts with CDC73 (PubMed:26742426). Interacts with
CC       CEACAM1 (via cytoplasmic domain); this interaction depends on the
CC       monomer/dimer equilibrium and is phosphorylation-dependent (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:P35235,
CC       ECO:0000269|PubMed:10068651, ECO:0000269|PubMed:10209036,
CC       ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:10681522,
CC       ECO:0000269|PubMed:11162587, ECO:0000269|PubMed:11389028,
CC       ECO:0000269|PubMed:11414741, ECO:0000269|PubMed:11433379,
CC       ECO:0000269|PubMed:12972546, ECO:0000269|PubMed:14597715,
CC       ECO:0000269|PubMed:15102829, ECO:0000269|PubMed:16885344,
CC       ECO:0000269|PubMed:16956752, ECO:0000269|PubMed:17213291,
CC       ECO:0000269|PubMed:18604210, ECO:0000269|PubMed:18829466,
CC       ECO:0000269|PubMed:19342684, ECO:0000269|PubMed:19509291,
CC       ECO:0000269|PubMed:20170098, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:26742426, ECO:0000269|PubMed:7691811,
CC       ECO:0000269|PubMed:8810330, ECO:0000269|PubMed:9062191,
CC       ECO:0000269|PubMed:9600074}.
CC   -!- INTERACTION:
CC       P10275:AR; NbExp=12; IntAct=EBI-297779, EBI-608057;
CC       P32239:CCKBR; NbExp=5; IntAct=EBI-297779, EBI-1753137;
CC       Q9BZW8:CD244; NbExp=5; IntAct=EBI-297779, EBI-1580565;
CC       P20138:CD33; NbExp=5; IntAct=EBI-297779, EBI-3906571;
CC       Q08345:DDR1; NbExp=4; IntAct=EBI-297779, EBI-711879;
CC       P68105:EEF1A1 (xeno); NbExp=2; IntAct=EBI-297779, EBI-7645934;
CC       Q71V39:EEF1A2 (xeno); NbExp=2; IntAct=EBI-297779, EBI-7645815;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-297779, EBI-641062;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-297779, EBI-1026718;
CC       Q13480:GAB1; NbExp=39; IntAct=EBI-297779, EBI-517684;
CC       Q9UQC2:GAB2; NbExp=4; IntAct=EBI-297779, EBI-975200;
CC       P62993:GRB2; NbExp=6; IntAct=EBI-297779, EBI-401755;
CC       P08069:IGF1R; NbExp=3; IntAct=EBI-297779, EBI-475981;
CC       P06213:INSR; NbExp=2; IntAct=EBI-297779, EBI-475899;
CC       P35568:IRS1; NbExp=3; IntAct=EBI-297779, EBI-517592;
CC       P35570:Irs1 (xeno); NbExp=3; IntAct=EBI-297779, EBI-520230;
CC       P43628:KIR2DL3; NbExp=4; IntAct=EBI-297779, EBI-8632435;
CC       P10721:KIT; NbExp=29; IntAct=EBI-297779, EBI-1379503;
CC       P08581:MET; NbExp=13; IntAct=EBI-297779, EBI-1039152;
CC       O95297:MPZL1; NbExp=4; IntAct=EBI-297779, EBI-963338;
CC       P09619:PDGFRB; NbExp=8; IntAct=EBI-297779, EBI-641237;
CC       P16284:PECAM1; NbExp=7; IntAct=EBI-297779, EBI-716404;
CC       P49023:PXN; NbExp=3; IntAct=EBI-297779, EBI-702209;
CC       P49247:RPIA; NbExp=4; IntAct=EBI-297779, EBI-744831;
CC       P97710:Sirpa (xeno); NbExp=3; IntAct=EBI-297779, EBI-7945080;
CC       Q13049:TRIM32; NbExp=3; IntAct=EBI-297779, EBI-742790;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:26742426}.
CC       Nucleus {ECO:0000269|PubMed:26742426}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=PTP2Ci;
CC         IsoId=Q06124-1; Sequence=Displayed;
CC       Name=2; Synonyms=PTP2C;
CC         IsoId=Q06124-2; Sequence=VSP_016672;
CC       Name=3;
CC         IsoId=Q06124-3; Sequence=VSP_016672, VSP_016673, VSP_016674;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in
CC       heart, brain, and skeletal muscle. {ECO:0000269|PubMed:1280823,
CC       ECO:0000269|PubMed:7681589, ECO:0000269|PubMed:8216283}.
CC   -!- DOMAIN: The SH2 domains repress phosphatase activity. Binding of
CC       these domains to phosphotyrosine-containing proteins relieves this
CC       auto-inhibition, possibly by inducing a conformational change in
CC       the enzyme.
CC   -!- PTM: Phosphorylated on Tyr-546 and Tyr-584 upon receptor protein
CC       tyrosine kinase activation; which creates a binding site for GRB2
CC       and other SH2-containing proteins. Phosphorylated upon activation
CC       of the receptor-type kinase FLT3. Phosphorylated upon activation
CC       of the receptor-type kinase PDGFRA (By similarity). Phosphorylated
CC       by activated PDGFRB. {ECO:0000250, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:7681217, ECO:0000269|PubMed:7691811,
CC       ECO:0000269|PubMed:8041791}.
CC   -!- DISEASE: LEOPARD syndrome 1 (LPRD1) [MIM:151100]: A disorder
CC       characterized by lentigines, electrocardiographic conduction
CC       abnormalities, ocular hypertelorism, pulmonic stenosis,
CC       abnormalities of genitalia, retardation of growth, and
CC       sensorineural deafness. {ECO:0000269|PubMed:12058348,
CC       ECO:0000269|PubMed:14961557, ECO:0000269|PubMed:15121796,
CC       ECO:0000269|PubMed:15389709, ECO:0000269|PubMed:15520399,
CC       ECO:0000269|PubMed:15690106, ECO:0000269|PubMed:16679933,
CC       ECO:0000269|PubMed:16733669, ECO:0000269|PubMed:24891296,
CC       ECO:0000269|PubMed:26742426}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan
CC       syndrome, a disease characterized by short stature, facial
CC       dysmorphic features such as hypertelorism, a downward eyeslant and
CC       low-set posteriorly rotated ears, and a high incidence of
CC       congenital heart defects and hypertrophic cardiomyopathy. Other
CC       features can include a short neck with webbing or redundancy of
CC       skin, deafness, motor delay, variable intellectual deficits,
CC       multiple skeletal defects, cryptorchidism, and bleeding diathesis.
CC       Individuals with Noonan syndrome are at risk of juvenile
CC       myelomonocytic leukemia, a myeloproliferative disorder
CC       characterized by excessive production of myelomonocytic cells.
CC       Some patients with NS1 develop multiple giant cell lesions of the
CC       jaw or other bony or soft tissues, which are classified as
CC       pigmented villonodular synovitis (PVNS) when occurring in the jaw
CC       or joints. {ECO:0000269|PubMed:11704759,
CC       ECO:0000269|PubMed:11992261, ECO:0000269|PubMed:12161469,
CC       ECO:0000269|PubMed:12325025, ECO:0000269|PubMed:12529711,
CC       ECO:0000269|PubMed:12634870, ECO:0000269|PubMed:12717436,
CC       ECO:0000269|PubMed:12739139, ECO:0000269|PubMed:12960218,
CC       ECO:0000269|PubMed:15384080, ECO:0000269|PubMed:15889278,
CC       ECO:0000269|PubMed:15948193, ECO:0000269|PubMed:19020799,
CC       ECO:0000269|PubMed:24891296, ECO:0000269|PubMed:28074573}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. Mutations in PTPN11 account for more
CC       than 50% of the cases.
CC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An
CC       aggressive pediatric myelodysplastic syndrome/myeloproliferative
CC       disorder characterized by malignant transformation in the
CC       hematopoietic stem cell compartment with proliferation of
CC       differentiated progeny. Patients have splenomegaly, enlarged lymph
CC       nodes, rashes, and hemorrhages. {ECO:0000269|PubMed:12717436,
CC       ECO:0000269|PubMed:26742426}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Metachondromatosis (MC) [MIM:156250]: A skeletal disorder
CC       with radiologic features of both multiple exostoses and Ollier
CC       disease, characterized by the presence of exostoses, commonly of
CC       the bones of the hands and feet, and enchondromas of the
CC       metaphyses of long bones and iliac crest.
CC       {ECO:0000269|PubMed:20577567}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class 2 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTPN11ID41910ch12q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D13540; BAA02740.2; -; mRNA.
DR   EMBL; L03535; AAA36611.1; -; mRNA.
DR   EMBL; L07527; AAA17022.1; -; mRNA.
DR   EMBL; L08807; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X70766; CAA50045.1; -; mRNA.
DR   EMBL; BT007106; AAP35770.1; -; mRNA.
DR   EMBL; AK289854; BAF82543.1; -; mRNA.
DR   EMBL; CH471054; EAW98012.1; -; Genomic_DNA.
DR   EMBL; BC008692; AAH08692.1; -; mRNA.
DR   CCDS; CCDS58280.1; -. [Q06124-3]
DR   CCDS; CCDS81741.1; -. [Q06124-1]
DR   CCDS; CCDS9163.1; -. [Q06124-2]
DR   PIR; JN0805; JN0805.
DR   RefSeq; NP_001317366.1; NM_001330437.1. [Q06124-1]
DR   RefSeq; NP_002825.3; NM_002834.4. [Q06124-2]
DR   RefSeq; NP_542168.1; NM_080601.2. [Q06124-3]
DR   UniGene; Hs.506852; -.
DR   PDB; 2SHP; X-ray; 2.00 A; A/B=1-529.
DR   PDB; 3B7O; X-ray; 1.60 A; A=237-533.
DR   PDB; 3MOW; X-ray; 2.30 A; A=262-532.
DR   PDB; 3O5X; X-ray; 2.00 A; A=262-532.
DR   PDB; 3TKZ; X-ray; 1.80 A; A=1-106.
DR   PDB; 3TL0; X-ray; 2.05 A; A=1-106.
DR   PDB; 3ZM0; X-ray; 1.50 A; A=248-531.
DR   PDB; 3ZM1; X-ray; 1.40 A; A=248-531.
DR   PDB; 3ZM2; X-ray; 1.50 A; A=248-531.
DR   PDB; 3ZM3; X-ray; 1.50 A; A=248-531.
DR   PDB; 4DGP; X-ray; 2.30 A; A=1-532.
DR   PDB; 4DGX; X-ray; 2.30 A; A=1-532.
DR   PDB; 4GWF; X-ray; 2.10 A; A/B=1-543.
DR   PDB; 4H1O; X-ray; 2.20 A; A=1-543.
DR   PDB; 4H34; X-ray; 2.70 A; A=1-543.
DR   PDB; 4JE4; X-ray; 2.31 A; A=1-103.
DR   PDB; 4JEG; X-ray; 2.30 A; A=97-217.
DR   PDB; 4JMG; X-ray; 1.40 A; B=579-591.
DR   PDB; 4NWF; X-ray; 2.10 A; A/B=1-543.
DR   PDB; 4NWG; X-ray; 2.45 A; A/B=1-543.
DR   PDB; 4OHD; X-ray; 2.70 A; A=1-532.
DR   PDB; 4OHE; X-ray; 2.51 A; A=1-467, A=469-532.
DR   PDB; 4OHH; X-ray; 2.70 A; A=1-532.
DR   PDB; 4OHI; X-ray; 2.20 A; A=1-532.
DR   PDB; 4OHL; X-ray; 2.40 A; A/B=1-532.
DR   PDB; 4PVG; X-ray; 2.40 A; A=240-532.
DR   PDB; 4QSY; X-ray; 2.10 A; A=1-106.
DR   PDB; 4RDD; X-ray; 1.60 A; A=262-532.
DR   PDB; 5DF6; X-ray; 1.78 A; A=1-222.
DR   PDB; 5EHP; X-ray; 1.85 A; A/B=1-529.
DR   PDB; 5EHR; X-ray; 1.70 A; A/B=1-529.
DR   PDB; 5I6V; X-ray; 1.87 A; A/B=1-529.
DR   PDB; 5IBM; X-ray; 2.18 A; A/B=1-529.
DR   PDB; 5IBS; X-ray; 2.32 A; A/B=1-529.
DR   PDBsum; 2SHP; -.
DR   PDBsum; 3B7O; -.
DR   PDBsum; 3MOW; -.
DR   PDBsum; 3O5X; -.
DR   PDBsum; 3TKZ; -.
DR   PDBsum; 3TL0; -.
DR   PDBsum; 3ZM0; -.
DR   PDBsum; 3ZM1; -.
DR   PDBsum; 3ZM2; -.
DR   PDBsum; 3ZM3; -.
DR   PDBsum; 4DGP; -.
DR   PDBsum; 4DGX; -.
DR   PDBsum; 4GWF; -.
DR   PDBsum; 4H1O; -.
DR   PDBsum; 4H34; -.
DR   PDBsum; 4JE4; -.
DR   PDBsum; 4JEG; -.
DR   PDBsum; 4JMG; -.
DR   PDBsum; 4NWF; -.
DR   PDBsum; 4NWG; -.
DR   PDBsum; 4OHD; -.
DR   PDBsum; 4OHE; -.
DR   PDBsum; 4OHH; -.
DR   PDBsum; 4OHI; -.
DR   PDBsum; 4OHL; -.
DR   PDBsum; 4PVG; -.
DR   PDBsum; 4QSY; -.
DR   PDBsum; 4RDD; -.
DR   PDBsum; 5DF6; -.
DR   PDBsum; 5EHP; -.
DR   PDBsum; 5EHR; -.
DR   PDBsum; 5I6V; -.
DR   PDBsum; 5IBM; -.
DR   PDBsum; 5IBS; -.
DR   ProteinModelPortal; Q06124; -.
DR   SMR; Q06124; -.
DR   BioGrid; 111745; 125.
DR   DIP; DIP-516N; -.
DR   IntAct; Q06124; 68.
DR   MINT; MINT-199832; -.
DR   STRING; 9606.ENSP00000340944; -.
DR   BindingDB; Q06124; -.
DR   ChEMBL; CHEMBL3864; -.
DR   DrugBank; DB02779; Dodecane-Trimethylamine.
DR   DEPOD; Q06124; -.
DR   iPTMnet; Q06124; -.
DR   PhosphoSitePlus; Q06124; -.
DR   BioMuta; PTPN11; -.
DR   DMDM; 84028248; -.
DR   EPD; Q06124; -.
DR   MaxQB; Q06124; -.
DR   PaxDb; Q06124; -.
DR   PeptideAtlas; Q06124; -.
DR   PRIDE; Q06124; -.
DR   TopDownProteomics; Q06124-2; -. [Q06124-2]
DR   DNASU; 5781; -.
DR   Ensembl; ENST00000351677; ENSP00000340944; ENSG00000179295. [Q06124-2]
DR   Ensembl; ENST00000392597; ENSP00000376376; ENSG00000179295. [Q06124-3]
DR   Ensembl; ENST00000635625; ENSP00000489597; ENSG00000179295. [Q06124-1]
DR   GeneID; 5781; -.
DR   KEGG; hsa:5781; -.
DR   UCSC; uc001ttw.2; human. [Q06124-1]
DR   CTD; 5781; -.
DR   DisGeNET; 5781; -.
DR   GeneCards; PTPN11; -.
DR   GeneReviews; PTPN11; -.
DR   HGNC; HGNC:9644; PTPN11.
DR   HPA; CAB005377; -.
DR   MalaCards; PTPN11; -.
DR   MIM; 151100; phenotype.
DR   MIM; 156250; phenotype.
DR   MIM; 163950; phenotype.
DR   MIM; 176876; gene.
DR   MIM; 607785; phenotype.
DR   neXtProt; NX_Q06124; -.
DR   OpenTargets; ENSG00000179295; -.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 500; LEOPARD syndrome.
DR   Orphanet; 2499; Metachondromatosis.
DR   Orphanet; 648; Noonan syndrome.
DR   PharmGKB; PA33986; -.
DR   eggNOG; KOG0790; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136380; -.
DR   HOGENOM; HOG000273907; -.
DR   HOVERGEN; HBG000223; -.
DR   InParanoid; Q06124; -.
DR   KO; K07293; -.
DR   OMA; KEYGAMR; -.
DR   OrthoDB; EOG091G0VZ3; -.
DR   PhylomeDB; Q06124; -.
DR   TreeFam; TF351632; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1170546; Prolactin receptor signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-210990; PECAM1 interactions.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2586552; Signaling by Leptin.
DR   Reactome; R-HSA-388841; Costimulation by the CD28 family.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-389948; PD-1 signaling.
DR   Reactome; R-HSA-391160; Signal regulatory protein (SIRP) family interactions.
DR   Reactome; R-HSA-418886; Netrin mediated repulsion signals.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-HSA-5654693; FRS-mediated FGFR1 signaling.
DR   Reactome; R-HSA-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-HSA-5654700; FRS-mediated FGFR2 signaling.
DR   Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-HSA-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-HSA-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-8865999; MET activates PTPN11.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-912694; Regulation of IFNA signaling.
DR   Reactome; R-HSA-936964; Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon.
DR   SignaLink; Q06124; -.
DR   SIGNOR; Q06124; -.
DR   ChiTaRS; PTPN11; human.
DR   EvolutionaryTrace; Q06124; -.
DR   GeneWiki; PTPN11; -.
DR   GenomeRNAi; 5781; -.
DR   PRO; PR:Q06124; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000179295; -.
DR   CleanEx; HS_PTPN11; -.
DR   ExpressionAtlas; Q06124; baseline and differential.
DR   Genevisible; Q06124; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:Reactome.
DR   GO; GO:0050839; F:cell adhesion molecule binding; IEA:Ensembl.
DR   GO; GO:0031748; F:D1 dopamine receptor binding; IEA:Ensembl.
DR   GO; GO:0005158; F:insulin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl.
DR   GO; GO:0004726; F:non-membrane spanning protein tyrosine phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0051428; F:peptide hormone receptor binding; IEA:Ensembl.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0043274; F:phospholipase binding; IEA:Ensembl.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IEA:Ensembl.
DR   GO; GO:0005070; F:SH3/SH2 adaptor activity; IPI:BHF-UCL.
DR   GO; GO:0033277; P:abortive mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0000187; P:activation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0036302; P:atrioventricular canal development; IMP:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IMP:BHF-UCL.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0021697; P:cerebellar cortex formation; IEA:Ensembl.
DR   GO; GO:0000077; P:DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038127; P:ERBB signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060325; P:face morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048806; P:genitalia development; IMP:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IMP:BHF-UCL.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0048839; P:inner ear development; IMP:BHF-UCL.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0061582; P:intestinal epithelial cell migration; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0035855; P:megakaryocyte development; IEA:Ensembl.
DR   GO; GO:0032528; P:microvillus organization; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0048609; P:multicellular organismal reproductive process; IEA:Ensembl.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IEA:Ensembl.
DR   GO; GO:0051463; P:negative regulation of cortisol secretion; IEA:Ensembl.
DR   GO; GO:0060125; P:negative regulation of growth hormone secretion; IEA:Ensembl.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0035265; P:organ growth; IEA:Ensembl.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0030220; P:platelet formation; IEA:Ensembl.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:2001275; P:positive regulation of glucose import in response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IMP:UniProtKB.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0043254; P:regulation of protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0046825; P:regulation of protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0006641; P:triglyceride metabolic process; IEA:Ensembl.
DR   Gene3D; 3.30.505.10; -; 2.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR012152; Tyr_Pase_non-rcpt_typ-6/11.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00017; SH2; 2.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000929; Tyr-Ptase_nr_6; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SMART; SM00252; SH2; 2.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Deafness; Disease mutation; Hydrolase; Nucleus;
KW   Phosphoprotein; Protein phosphatase; Reference proteome; Repeat;
KW   SH2 domain.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    597       Tyrosine-protein phosphatase non-receptor
FT                                type 11.
FT                                /FTId=PRO_0000094767.
FT   DOMAIN        6    102       SH2 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      112    216       SH2 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      247    521       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      463    469       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    463    463       Phosphocysteine intermediate.
FT   BINDING     429    429       Substrate. {ECO:0000250}.
FT   BINDING     510    510       Substrate. {ECO:0000250}.
FT   MOD_RES       2      2       N-acetylthreonine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      62     62       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES      66     66       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P35235}.
FT   MOD_RES     546    546       Phosphotyrosine; by PDGFR.
FT                                {ECO:0000250|UniProtKB:P35235}.
FT   MOD_RES     584    584       Phosphotyrosine; by PDGFR.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     408    411       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:1280823,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7681217,
FT                                ECO:0000303|PubMed:7681589,
FT                                ECO:0000303|PubMed:8216283,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_016672.
FT   VAR_SEQ     464    464       S -> R (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_016673.
FT   VAR_SEQ     465    597       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_016674.
FT   VARIANT       2      2       T -> I (in NS1; dbSNP:rs267606990).
FT                                {ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_027183.
FT   VARIANT      42     42       T -> A (in NS1; dbSNP:rs397507501).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015601.
FT   VARIANT      58     58       N -> K (in NS1; dbSNP:rs397507506).
FT                                {ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_027184.
FT   VARIANT      59     59       T -> A (in NS1).
FT                                {ECO:0000269|PubMed:19020799}.
FT                                /FTId=VAR_066060.
FT   VARIANT      60     60       G -> A (in NS1; dbSNP:rs397507509).
FT                                {ECO:0000269|PubMed:11992261}.
FT                                /FTId=VAR_015602.
FT   VARIANT      60     60       G -> V (in myelodysplastic syndrome;
FT                                dbSNP:rs397507509).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015990.
FT   VARIANT      61     61       D -> G (in NS1; dbSNP:rs121918461).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12161469,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015603.
FT   VARIANT      61     61       D -> N (in NS1; dbSNP:rs397507510).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015604.
FT   VARIANT      61     61       D -> V (in JMML; also in myelodysplastic
FT                                syndrome; dbSNP:rs121918461).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015991.
FT   VARIANT      61     61       D -> Y (in JMML).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015992.
FT   VARIANT      62     62       Y -> D (in NS1; also in Noonan patients
FT                                manifesting juvenile myelomonocytic
FT                                leukemia; dbSNP:rs121918460).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12325025,
FT                                ECO:0000269|PubMed:12717436,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015605.
FT   VARIANT      63     63       Y -> C (in NS1; dbSNP:rs121918459).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12161469,
FT                                ECO:0000269|PubMed:12325025,
FT                                ECO:0000269|PubMed:12634870,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015606.
FT   VARIANT      69     69       E -> K (in JMML; also in myelodysplastic
FT                                syndrome). {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015993.
FT   VARIANT      69     69       E -> Q (in NS1; dbSNP:rs397507511).
FT                                {ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_027185.
FT   VARIANT      71     71       F -> K (in acute myeloid leukemia;
FT                                requires 2 nucleotide substitutions).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015994.
FT   VARIANT      71     71       F -> L (in myelodysplastic syndrome;
FT                                dbSNP:rs397507512).
FT                                {ECO:0000269|PubMed:12634870,
FT                                ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015995.
FT   VARIANT      72     72       A -> G (in NS1; dbSNP:rs121918454).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015607.
FT   VARIANT      72     72       A -> S (in NS1; dbSNP:rs121918453).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:12161469,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015608.
FT   VARIANT      72     72       A -> T (in JMML; dbSNP:rs121918453).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015996.
FT   VARIANT      72     72       A -> V (in JMML; dbSNP:rs121918454).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015997.
FT   VARIANT      73     73       T -> I (in NS1; also in Noonan patients
FT                                manifesting juvenile myelomonocytic
FT                                leukemia; dbSNP:rs28933387).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12161469,
FT                                ECO:0000269|PubMed:12634870,
FT                                ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015609.
FT   VARIANT      76     76       E -> A (in JMML; also in myelodysplastic
FT                                syndrome; dbSNP:rs121918465).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015998.
FT   VARIANT      76     76       E -> D (in NS1; dbSNP:rs397507514).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015610.
FT   VARIANT      76     76       E -> G (in JMML; dbSNP:rs121918465).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_015999.
FT   VARIANT      76     76       E -> K (in JMML; increases protein
FT                                tyrosine phosphatase activity against
FT                                CDC73; dbSNP:rs28933388).
FT                                {ECO:0000269|PubMed:12717436,
FT                                ECO:0000269|PubMed:26742426}.
FT                                /FTId=VAR_016000.
FT   VARIANT      76     76       E -> V (in JMML; dbSNP:rs121918465).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_016001.
FT   VARIANT      79     79       Q -> P (in NS1).
FT                                {ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_027186.
FT   VARIANT      79     79       Q -> R (in NS1; dbSNP:rs121918466).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12529711,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015611.
FT   VARIANT     106    106       D -> A (in NS1; dbSNP:rs397507517).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015612.
FT   VARIANT     139    139       E -> D (in NS1; dbSNP:rs397507520).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015613.
FT   VARIANT     256    256       Q -> R (in NS1; dbSNP:rs397507523).
FT                                {ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_027187.
FT   VARIANT     261    261       L -> F (in NS1; increases MAPK signaling;
FT                                increases protein tyrosine phosphatase
FT                                activity; changed substrate selectivity
FT                                for GAB1). {ECO:0000269|PubMed:28074573}.
FT                                /FTId=VAR_078101.
FT   VARIANT     261    261       L -> H (in NS1; increases MAPK signaling;
FT                                increased protein tyrosine phosphatase
FT                                activity). {ECO:0000269|PubMed:28074573}.
FT                                /FTId=VAR_078102.
FT   VARIANT     262    262       L -> F (in NS1; increases MAPK signaling;
FT                                increased protein tyrosine phosphatase
FT                                activity). {ECO:0000269|PubMed:28074573}.
FT                                /FTId=VAR_078103.
FT   VARIANT     262    262       L -> R (in NS1; increases MAPK signaling;
FT                                increased protein tyrosine phosphatase
FT                                activity). {ECO:0000269|PubMed:28074573}.
FT                                /FTId=VAR_078104.
FT   VARIANT     265    265       R -> Q (in NS1; increases MAPK signaling;
FT                                increased protein tyrosine phosphatase
FT                                activity). {ECO:0000269|PubMed:28074573}.
FT                                /FTId=VAR_078105.
FT   VARIANT     279    279       Y -> C (in NS1 and LPRD1; does not affect
FT                                subcellular location; decreases protein
FT                                tyrosine phosphatase activity against
FT                                CDC73; dbSNP:rs121918456).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12058348,
FT                                ECO:0000269|PubMed:12960218,
FT                                ECO:0000269|PubMed:15121796,
FT                                ECO:0000269|PubMed:15520399,
FT                                ECO:0000269|PubMed:16679933,
FT                                ECO:0000269|PubMed:26742426}.
FT                                /FTId=VAR_015614.
FT   VARIANT     279    279       Y -> S (in LPRD1; dbSNP:rs121918456).
FT                                {ECO:0000269|PubMed:15121796,
FT                                ECO:0000269|PubMed:15520399}.
FT                                /FTId=VAR_027188.
FT   VARIANT     282    282       I -> V (in NS1; dbSNP:rs397507529).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12634870}.
FT                                /FTId=VAR_015615.
FT   VARIANT     285    285       F -> L (in NS1; dbSNP:rs397507531).
FT                                {ECO:0000269|PubMed:11992261}.
FT                                /FTId=VAR_015617.
FT   VARIANT     285    285       F -> S (in NS1; dbSNP:rs121918463).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12161469}.
FT                                /FTId=VAR_015616.
FT   VARIANT     308    308       N -> D (in NS1; common mutation;
FT                                dbSNP:rs28933386).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12161469,
FT                                ECO:0000269|PubMed:12634870,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015619.
FT   VARIANT     308    308       N -> S (in NS1; some patients also
FT                                manifest giant cell lesions of bone and
FT                                soft tissue; dbSNP:rs121918455).
FT                                {ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015618.
FT   VARIANT     309    309       I -> V (in NS1; unknown pathological
FT                                significance; dbSNP:rs201787206).
FT                                {ECO:0000269|PubMed:11992261}.
FT                                /FTId=VAR_015620.
FT   VARIANT     415    415       T -> M (in NS1; dbSNP:rs121918467).
FT                                {ECO:0000269|PubMed:15384080}.
FT                                /FTId=VAR_027189.
FT   VARIANT     465    465       A -> T (in LPRD1; dbSNP:rs121918468).
FT                                {ECO:0000269|PubMed:15389709}.
FT                                /FTId=VAR_027190.
FT   VARIANT     468    468       G -> A (in LPRD1; dbSNP:rs121918469).
FT                                {ECO:0000269|PubMed:15121796,
FT                                ECO:0000269|PubMed:15389709}.
FT                                /FTId=VAR_027191.
FT   VARIANT     472    472       T -> M (in LPRD1; does not affect
FT                                subcellular location; decreases protein
FT                                tyrosine phosphatase activity against
FT                                CDC73; dbSNP:rs121918457).
FT                                {ECO:0000269|PubMed:12058348,
FT                                ECO:0000269|PubMed:12960218,
FT                                ECO:0000269|PubMed:15121796,
FT                                ECO:0000269|PubMed:15520399,
FT                                ECO:0000269|PubMed:26742426}.
FT                                /FTId=VAR_015621.
FT   VARIANT     495    495       P -> S (in NS1; increased phosphatase
FT                                activity; dbSNP:rs397507539).
FT                                {ECO:0000269|PubMed:24891296}.
FT                                /FTId=VAR_071706.
FT   VARIANT     502    502       R -> L (in LPRD1; dbSNP:rs397507542).
FT                                {ECO:0000269|PubMed:15121796}.
FT                                /FTId=VAR_027192.
FT   VARIANT     502    502       R -> W (in LPRD1; reduced phosphatase
FT                                activity; dbSNP:rs397507541).
FT                                {ECO:0000269|PubMed:15121796,
FT                                ECO:0000269|PubMed:24891296}.
FT                                /FTId=VAR_027193.
FT   VARIANT     505    505       R -> K (in NS1; dbSNP:rs397507543).
FT                                {ECO:0000269|PubMed:11992261}.
FT                                /FTId=VAR_015622.
FT   VARIANT     506    506       S -> T (in NS1; dbSNP:rs121918458).
FT                                {ECO:0000269|PubMed:12325025,
FT                                ECO:0000269|PubMed:12739139}.
FT                                /FTId=VAR_015623.
FT   VARIANT     507    507       G -> A (in JMML; dbSNP:rs397507546).
FT                                {ECO:0000269|PubMed:12717436}.
FT                                /FTId=VAR_016002.
FT   VARIANT     507    507       G -> R (in NS1 and JMML; JMML patient
FT                                also shows growth retardation and
FT                                pulmonic stenosis; dbSNP:rs397507545).
FT                                {ECO:0000269|PubMed:12717436,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_016003.
FT   VARIANT     508    508       M -> V (in NS1; dbSNP:rs397507547).
FT                                {ECO:0000269|PubMed:11704759,
FT                                ECO:0000269|PubMed:11992261,
FT                                ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_015624.
FT   VARIANT     510    510       Q -> P (in LPRD1; does not affect
FT                                subcellular location; decreases protein
FT                                tyrosine phosphatase activity against
FT                                CDC73; dbSNP:rs397509345).
FT                                {ECO:0000269|PubMed:14961557,
FT                                ECO:0000269|PubMed:15121796,
FT                                ECO:0000269|PubMed:15690106,
FT                                ECO:0000269|PubMed:26742426}.
FT                                /FTId=VAR_027194.
FT   VARIANT     510    510       Q -> R (in NS1).
FT                                {ECO:0000269|PubMed:15948193}.
FT                                /FTId=VAR_027195.
FT   VARIANT     514    514       Q -> E (in NS1 and LPRD1; does not affect
FT                                subcellular location; decreases protein
FT                                tyrosine phosphatase activity against
FT                                CDC73; dbSNP:rs397507549).
FT                                {ECO:0000269|PubMed:15889278,
FT                                ECO:0000269|PubMed:16733669,
FT                                ECO:0000269|PubMed:26742426}.
FT                                /FTId=VAR_076499.
FT   VARIANT     514    514       Q -> P (in LPRD1; dbSNP:rs121918470).
FT                                {ECO:0000269|PubMed:15520399}.
FT                                /FTId=VAR_027196.
FT   VARIANT     564    564       L -> F (in NS1; dbSNP:rs397516797).
FT                                {ECO:0000269|PubMed:12960218}.
FT                                /FTId=VAR_027197.
FT   MUTAGEN     463    463       C->S: Abolishes phosphatase activity.
FT                                {ECO:0000269|PubMed:8216283}.
FT   CONFLICT    539    539       S -> R (in Ref. 3; BAA02740).
FT                                {ECO:0000305}.
FT   CONFLICT    552    552       S -> P (in Ref. 3; BAA02740).
FT                                {ECO:0000305}.
FT   TURN          3      6       {ECO:0000244|PDB:4OHD}.
FT   HELIX        13     23       {ECO:0000244|PDB:5EHR}.
FT   STRAND       28     33       {ECO:0000244|PDB:5EHR}.
FT   STRAND       35     37       {ECO:0000244|PDB:5EHR}.
FT   STRAND       41     47       {ECO:0000244|PDB:5EHR}.
FT   STRAND       50     57       {ECO:0000244|PDB:5EHR}.
FT   STRAND       59     61       {ECO:0000244|PDB:5EHR}.
FT   STRAND       63     65       {ECO:0000244|PDB:5EHR}.
FT   STRAND       70     73       {ECO:0000244|PDB:5EHR}.
FT   HELIX        74     82       {ECO:0000244|PDB:5EHR}.
FT   STRAND       83     85       {ECO:0000244|PDB:4OHD}.
FT   STRAND       87     90       {ECO:0000244|PDB:3TKZ}.
FT   STRAND       91     93       {ECO:0000244|PDB:4NWG}.
FT   HELIX       107    109       {ECO:0000244|PDB:4DGX}.
FT   STRAND      113    116       {ECO:0000244|PDB:5EHP}.
FT   HELIX       119    129       {ECO:0000244|PDB:5EHR}.
FT   STRAND      134    139       {ECO:0000244|PDB:5EHR}.
FT   STRAND      141    143       {ECO:0000244|PDB:5DF6}.
FT   STRAND      147    153       {ECO:0000244|PDB:5EHR}.
FT   STRAND      154    156       {ECO:0000244|PDB:5DF6}.
FT   STRAND      166    175       {ECO:0000244|PDB:5EHR}.
FT   STRAND      178    184       {ECO:0000244|PDB:5EHR}.
FT   STRAND      187    189       {ECO:0000244|PDB:5EHR}.
FT   HELIX       190    199       {ECO:0000244|PDB:5EHR}.
FT   STRAND      202    204       {ECO:0000244|PDB:5DF6}.
FT   STRAND      208    210       {ECO:0000244|PDB:4JEG}.
FT   STRAND      218    222       {ECO:0000244|PDB:4OHD}.
FT   HELIX       223    225       {ECO:0000244|PDB:5EHR}.
FT   HELIX       226    234       {ECO:0000244|PDB:5EHR}.
FT   HELIX       251    253       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       256    258       {ECO:0000244|PDB:4PVG}.
FT   HELIX       259    262       {ECO:0000244|PDB:3B7O}.
FT   HELIX       266    269       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       271    276       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      277    279       {ECO:0000244|PDB:2SHP}.
FT   HELIX       286    288       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      289    291       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      304    310       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      319    321       {ECO:0000244|PDB:4RDD}.
FT   HELIX       323    325       {ECO:0000244|PDB:5EHP}.
FT   STRAND      327    331       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       335    337       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       338    347       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      352    355       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      359    361       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      364    366       {ECO:0000244|PDB:3ZM0}.
FT   STRAND      376    380       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      383    392       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      394    405       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       413    415       {ECO:0000244|PDB:5I6V}.
FT   STRAND      417    424       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      429    431       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      434    436       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       437    451       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      459    467       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       468    486       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      488    492       {ECO:0000244|PDB:5EHR}.
FT   HELIX       494    502       {ECO:0000244|PDB:3ZM1}.
FT   HELIX       512    528       {ECO:0000244|PDB:3ZM1}.
FT   STRAND      585    589       {ECO:0000244|PDB:4JMG}.
SQ   SEQUENCE   597 AA;  68436 MW;  37E8BFC7ECA2D03F CRC64;
     MTSRRWFHPN ITGVEAENLL LTRGVDGSFL ARPSKSNPGD FTLSVRRNGA VTHIKIQNTG
     DYYDLYGGEK FATLAELVQY YMEHHGQLKE KNGDVIELKY PLNCADPTSE RWFHGHLSGK
     EAEKLLTEKG KHGSFLVRES QSHPGDFVLS VRTGDDKGES NDGKSKVTHV MIRCQELKYD
     VGGGERFDSL TDLVEHYKKN PMVETLGTVL QLKQPLNTTR INAAEIESRV RELSKLAETT
     DKVKQGFWEE FETLQQQECK LLYSRKEGQR QENKNKNRYK NILPFDHTRV VLHDGDPNEP
     VSDYINANII MPEFETKCNN SKPKKSYIAT QGCLQNTVND FWRMVFQENS RVIVMTTKEV
     ERGKSKCVKY WPDEYALKEY GVMRVRNVKE SAAHDYTLRE LKLSKVGQAL LQGNTERTVW
     QYHFRTWPDH GVPSDPGGVL DFLEEVHHKQ ESIMDAGPVV VHCSAGIGRT GTFIVIDILI
     DIIREKGVDC DIDVPKTIQM VRSQRSGMVQ TEAQYRFIYM AVQHYIETLQ RRIEEEQKSK
     RKGHEYTNIK YSLADQTSGD QSPLPPCTPT PPCAEMREDS ARVYENVGLM QQQKSFR
//
